✦ LIBER ✦

PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING

✍ Scribed by JL Palmer; VC Munk; R Kotchie; G Vincze; Charney k; D Tucker; L Annemans

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

196: Cost-Effectiveness of Aliskiren as

✍ James L. Palmer; Veronica C. Munk; Robert W. Kotchie; Gabor Vincze; Alan Charney 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB

PCV72 COST-EFFECTIVENESS ANALYSIS OF ADD

✍ P Kutscherauer; R Kodym; D Bartaskova 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

PDB3 COST-EFFECTIVENESS ANALYSIS OF INSU

✍ I Smith; AJ Palmer; S Roze; T Kennedy-Martin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Cost-Effectiveness of Insulin Degludec C

✍ Evans, M.; Chubb, B.; Christensen, T.; Gundgaard, J.; Wolden, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Effects of Losartan-based therapy on the

✍ Jiten Vora; George Carides; Paul Robinson 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 565 KB

PDB19 ESTIMATING THE COST EFFECTIVENESS

✍ A Brennan; M Gillett; A Duenas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB